Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Deputy Commissioner Pendergast to become Elan Exec VP-Government Affairs effective Jan. 5.

This article was originally published in The Gray Sheet

Executive Summary

FDA DEPUTY COMMISSIONER PENDERGAST TO BECOME ELAN EXEC VP-GOVERNMENT AFFAIRS following her resignation from the agency effective Jan. 2. Mary Pendergast will be based in Washington, D.C. in the newly created position. Elan, based in Athlone, Ireland, is primarily involved in drug delivery work, and its attempts to develop new formulations have occasionally raised regulatory issues at FDA. For example, Pfizer sought to prevent approval of Elan's sustained-release nifedipine formulation Nifelan via an FDA citizen's petition.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT009248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel